Updated: FDA approves Biogen and Sage's pill for postpartum depression, but rejects use in major depression

Ryan Cross

Senior Science Correspondent

The FDA has approved a first-of-its kind antidepressant pill that acts on a different brain chemical than existing drugs for depression, lifts moods in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

view job offer post your job now

TRENDING NOW

Updated: FDA approves Biogen and Sage's pill for postpartum depression, but rejects use in major depression

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

We’re about to find out which RFK Jr. will show up at HHS

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Astellas shakes up management despite impressive nine-month earnings

Illumina added to China's blacklist following Biosecure Act, tariffs

Up­dat­ed: FDA ap­proves Bio­gen and Sage's pill for post­par­tum de­pres­sion, but re­jects use in ma­jor de­pres­sion

Senior Science Correspondent

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Updated: FDA approves Biogen and Sage's pill for postpartum depression, but rejects use in major depression